Radium Ra-223
- Generic Name
- Radium Ra-223
- Drug Type
- Small Molecule
- Chemical Formula
- Ra
- CAS Number
- 15623-45-7
- Unique Ingredient Identifier
- 8BR2SOL3L1
- Background
Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT01934790
Japanese BAY88-8223 Monotherapy Phase II Study
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 49
- Registration Number
- NCT01929655
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Phase 3
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 243
- Registration Number
- NCT01810770
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 705
- Registration Number
- NCT01618370
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19
- Registration Number
- NCT01565746
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Bayer
- Registration Number
- NCT01516762
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Phase 1
Completed
- Conditions
- Castration-Resistant Prostate CancerBone Metastases
- Interventions
- First Posted Date
- 2010-04-19
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT01106352
BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease
Phase 2
Completed
- Conditions
- Breast CancerBone Metastases
- Interventions
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 23
- Registration Number
- NCT01070485
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
Phase 1
Completed
- Conditions
- Prostate CancerPharmacokineticsMetastases
- Interventions
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT00748046
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Phase 3
Completed
- Conditions
- Hormone Refractory Prostate CancerBone Metastases
- Interventions
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 921
- Registration Number
- NCT00699751
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath